These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 18794843)

  • 1. Activation of tyrosine kinases by mutation of the gatekeeper threonine.
    Azam M; Seeliger MA; Gray NS; Kuriyan J; Daley GQ
    Nat Struct Mol Biol; 2008 Oct; 15(10):1109-18. PubMed ID: 18794843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of the T315I mutant of AbI kinase.
    Zhou T; Parillon L; Li F; Wang Y; Keats J; Lamore S; Xu Q; Shakespeare W; Dalgarno D; Zhu X
    Chem Biol Drug Des; 2007 Sep; 70(3):171-81. PubMed ID: 17718712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.
    Dixit A; Verkhivker GM
    PLoS Comput Biol; 2009 Aug; 5(8):e1000487. PubMed ID: 19714203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
    Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
    Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
    Weisberg E; Choi HG; Ray A; Barrett R; Zhang J; Sim T; Zhou W; Seeliger M; Cameron M; Azam M; Fletcher JA; Debiec-Rychter M; Mayeda M; Moreno D; Kung AL; Janne PA; Khosravi-Far R; Melo JV; Manley PW; Adamia S; Wu C; Gray N; Griffin JD
    Blood; 2010 May; 115(21):4206-16. PubMed ID: 20299508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors.
    Panjarian S; Iacob RE; Chen S; Wales TE; Engen JR; Smithgall TE
    J Biol Chem; 2013 Mar; 288(9):6116-29. PubMed ID: 23303187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of mutant tyrosine kinase chemical rescue.
    Muratore KE; Seeliger MA; Wang Z; Fomina D; Neiswinger J; Havranek JJ; Baker D; Kuriyan J; Cole PA
    Biochemistry; 2009 Apr; 48(15):3378-86. PubMed ID: 19260709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation.
    Thiel KW; Carpenter G
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19238-43. PubMed ID: 18042729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
    Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the c-Abl and Bcr-Abl tyrosine kinases.
    Hantschel O; Superti-Furga G
    Nat Rev Mol Cell Biol; 2004 Jan; 5(1):33-44. PubMed ID: 14708008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.
    Azam M; Powers JT; Einhorn W; Huang WS; Shakespeare WC; Zhu X; Dalgarno D; Clackson T; Sawyer TK; Daley GQ
    Chem Biol Drug Des; 2010 Feb; 75(2):223-7. PubMed ID: 20028401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural study of ponatinib in inhibiting SRC kinase.
    Guo M; Duan Y; Dai S; Li J; Chen X; Qu L; Chen Z; Wei H; Jiang L; Chen Y
    Biochem Biophys Res Commun; 2022 Apr; 598():15-19. PubMed ID: 35151199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Abl Tyrosine Kinase Adopts Multiple Active Conformational States in Solution.
    Badger J; Grover P; Shi H; Panjarian SB; Engen JR; Smithgall TE; Makowski L
    Biochemistry; 2016 Jun; 55(23):3251-60. PubMed ID: 27166638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing.
    Patil R; Das S; Stanley A; Yadav L; Sudhakar A; Varma AK
    PLoS One; 2010 Aug; 5(8):e12029. PubMed ID: 20808434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein tyrosine kinases: autoregulation and small-molecule inhibition.
    Hubbard SR
    Curr Opin Struct Biol; 2002 Dec; 12(6):735-41. PubMed ID: 12504677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
    Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
    ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
    Modugno M; Casale E; Soncini C; Rosettani P; Colombo R; Lupi R; Rusconi L; Fancelli D; Carpinelli P; Cameron AD; Isacchi A; Moll J
    Cancer Res; 2007 Sep; 67(17):7987-90. PubMed ID: 17804707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlling the activity of the Tec kinase Itk by mutation of the phenylalanine gatekeeper residue.
    Joseph RE; Andreotti AH
    Biochemistry; 2011 Jan; 50(2):221-9. PubMed ID: 21138328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal regulation of Abl and receptor tyrosine kinases.
    Srinivasan D; Kaetzel DM; Plattner R
    Cell Signal; 2009 Jul; 21(7):1143-50. PubMed ID: 19275932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.